[{"NetIncomeLoss_1_Q2_USD":-49023000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":5639000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":15431251.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":15433348.0,"InterestIncomeOther_2_Q2_USD":3074000.0,"InterestIncomeOther_1_Q2_USD":1204000.0,"LiabilitiesNoncurrent_0_Q2_USD":197000.0,"AccruedLiabilitiesCurrent_0_Q2_USD":39948000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":1081000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":69825000.0,"AssetsCurrent_0_Q2_USD":386603000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":109000.0,"CommonStockSharesIssued_0_Q2_shares":15438124.0,"Assets_0_Q2_USD":388388000.0,"ShareBasedCompensation_2_Q2_USD":10535000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":520000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":10244000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"PreferredStockSharesOutstanding_0_Q2_shares":1969797.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":650211000.0,"OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_2_Q2_USD":865000.0,"OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1_Q2_USD":666000.0,"IncreaseDecreaseInAccruedLiabilities_2_Q2_USD":16311000.0,"CommonStockValue_0_Q2_USD":2000.0,"Revenues_2_Q2_USD":0.0,"Revenues_1_Q2_USD":0.0,"DepreciationDepletionAndAmortization_2_Q2_USD":240000.0,"ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_2_Q2_USD":78088000.0,"ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1_Q2_USD":44688000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":109000.0,"AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_1_Q2_USD":5689000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-84293000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-48357000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":61867000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":197000.0,"Liabilities_0_Q2_USD":45472000.0,"ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_2_Q2_USD":224015000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.0001,"IncreaseDecreaseInAccountsPayableTrade_2_Q2_USD":3826000.0,"OtherIncome_1_Q2_USD":100000.0,"RevenueFromContractWithCustomerIncludingAssessedTax_2_Q2_USD":0.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-308378000.0,"CommonStockSharesOutstanding_0_Q2_shares":15438124.0,"PaymentsToAcquireMarketableSecurities_2_Q2_USD":153869000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-54764000.0,"LiabilitiesCurrent_0_Q2_USD":45275000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_Q2_USD":15170000.0,"AccountsPayableCurrent_0_Q2_USD":5004000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":61867000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":2223000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":4967000.0,"PreferredStockSharesIssued_0_Q2_shares":1969797.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":1265000.0,"NetIncomeLoss_2_Q2_USD":-85158000.0,"OtherIncome_2_Q2_USD":100000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":1072000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":321000.0,"ProfitLoss_2_Q2_USD":-85158000.0,"CommonStockSharesAuthorized_0_Q2_shares":200000000.0,"OperatingIncomeLoss_2_Q2_USD":-88332000.0,"OperatingIncomeLoss_1_Q2_USD":-50327000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q2_USD":322513000.0,"PreferredStockValue_0_Q2_USD":null,"LiabilitiesAndStockholdersEquity_0_Q2_USD":388388000.0,"PreferredStockSharesAuthorized_0_Q2_shares":5000000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":10535000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":5689000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":323000.0,"OperatingExpenses_2_Q2_USD":88332000.0,"OperatingExpenses_1_Q2_USD":50327000.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2_Q2_USD":0.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-5.52,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-3.18,"StockholdersEquity_0_Q2_USD":342916000.0,"AccruedProfessionalFeesCurrent_0_Q2_USD":862000.0,"Ticker":"MDGL","CIK":"1157601","name":"MADRIGAL PHARMACEUTICALS, INC.","OfficialName":"Madrigal Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"1322434501.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20200806"}]